Summary The 'unopposed oestrogen hypothesis' for endometrial cancer maintains that risk is increased by exposure to endogenous or exogenous oestrogen that is not opposed simultaneously by a progestagen, and that this increased risk is due to the induced mitotic activity of the endometrial cells. Investigation of the mitotic rate during the menstrual cycle shows that increases in plasma oestrogen concentration above the relatively low levels of the early follicular phase do not produce any further increase in the mitotic rate of endometrial cells. A modification of the unopposed oestrogen hypothesis which includes this upper limit in the response of endometrial cells to oestrogen is consistent with the known dose-effect relationships between endometrial cancer risk and both oestrogen replacement therapy and postmenopausal obesity; it also suggests that the mechanism by which obesity increases risk in premenopausal women involves progesterone deficiency rather than oestrogen excess, and that the protective effect of cigarette smoking may be greater in postmenopausal than in premenopausal women.
Summary The 'unopposed oestrogen hypothesis' for endometrial cancer maintains that risk is increased by exposure to endogenous or exogenous oestrogen that is not opposed simultaneously by a progestagen, and that this increased risk is due to the induced mitotic activity of the endometrial cells. Investigation of the mitotic rate during the menstrual cycle shows that increases in plasma oestrogen concentration above the relatively low levels of the early follicular phase do not produce any further increase in the mitotic rate of endometrial cells. A modification of the unopposed oestrogen hypothesis which includes this upper limit in the response of endometrial cells to oestrogen is consistent with the known dose-effect relationships between endometrial cancer risk and both oestrogen replacement therapy and postmenopausal obesity; it also suggests that the mechanism by which obesity increases risk in premenopausal women involves progesterone deficiency rather than oestrogen excess, and that the protective effect of cigarette smoking may be greater in postmenopausal than in premenopausal women.
Detailed analysis of the age-incidence curve for endometrial cancer in the light of this hypothesis suggests that there will be lifelong effects of even short duration use of exogenous hormones. In particular, 5 years of combination-type oral contraceptive use is likely to reduce a woman's lifetime risk of endometrial cancer by some 60%; whereas 5 years of unopposed oestrogen replacement therapy is likely to increase her subsequent lifetime risk by at least 90%; and even 5 years of 'adequately' opposed therapy is likely to increase subsequent lifetime risk by at least 50%.
Epidemiological studies have shown that the risk of developing endometrial cancer increases markedly with increasing weight and with use of oestrogen replacement therapy (ERT) or sequential-type oral contraceptives, and decreases markedly with use of combination-type oral contraceptives (COCs) (Weiss et al., 1980; Henderson et al., 1983) . These risk factors can all be explained in terms of the 'unopposed oestrogen hypothesis' for endometrial cancer (Siiteri, 1978; Henderson et al., 1982) .
In essence the unopposed oestrogen hypothesis maintains that endometrial cancer risk is increased by exposure to endogenous or exogenous oestrogen which is not opposed by progesterone or a synthetic progestagen, and that this increased risk is caused by the increased mitotic activity of the endometrium induced by such exposure. It has, however, not been clear that this hypothesis can explain the high relative risk associated with obesity in premenopausal women.
In this paper we first argue, on the basis of studies of premenopausal hormone levels and of endometrial mitotic rates, that endometrial cell division is not increased by increases in plasma oestrogen concentration above early follicular levels. We show that epidemiological studies of the effects of different doses of ERT on endometrial cancer risk are consistent with the existence of such an upper limit, as are studies of the effects of obesity on risk in postmenopausal women. We then show how the existence of this upper limit to effective oestrogen action suggests that cigarette smoking has a different effect on endometrial cancer risk in pre-and postmenopausal women. We also explain why this upper limit suggests that the reason for the increased risk of endometrial cancer in obese premenopausal women is progesterone deficiency, not increased plasma oestrogen concentration.
Finally we show that analysis of the age-incidence curve of endometrial cancer in the context of the unopposed oestrogen hypothesis implies that ERT [see Henderson et al. (1982) for references].
Figure la shows the mitotic rate of the glandular endometrial cells (Ferenczy et al., 1979) and figure lb the fluctuating plasma concentrations of E2 and progesterone (Thorneycroft et al., 1971; Goebelsmann & Mishell, 1979) during the menstrual cycle. The two most important points to note from Figure 1 endometrium (very little mitotic activity), but there is little information available about the nature of the dose-effect relationship between unopposed E2 concentration and mitotic rate between such low concentrations and the upper limit. The existence of the upper limit has important implications. In particular the limit implies that in premenopausal women changes in E2 will have little effect: increases in E2 above 'normal' will not increase endometrial cell division, and decreases in E2 will, at most, only decrease mitotic activity for the few days of the cycle during which E2 is normally close to the basal 50 pg ml -1 level. In postmenopausal women, however, E2 is in the range of 5-20 pg ml -1, well below the upper limit. Increases in E2 will therefore increase the endometrial mitotic rate until the upper limit for E2 is reached, and decreases in E2 will decrease the mitotic rate until the (unknown) lower limit for E2 is reached.
Oestradiol binding Plasma E2 is mostly bound to protein: about half is bound with high affinity to sex hormone binding globulin (SHBG) and about half to albumin, with only -2% being nonprotein bound or 'free' (Anderson, 1974) . It is generally accepted that the non-protein bound E2 is free to reach intracellular receptors, and there is now increasingly persuasive evidence that the E2 bound to albumin may also be 'bioavailable' (Pardridge, 1986) . In discussing the likely effects of changes in E2 concentration it is therefore necessary on occasion to consider parallel changes in the protein binding of E2, which are largely determined by changes in SHBG concentration. To estimate % non-protein bound E2 and % non-SHBG bound E2 from knowledge of total E2 and SHBG we have used the regression equations given by Moore et al. (1983) .
Oestrogen replacement therapy dose Almost all studies of the relationship between ERT and endometrial cancer risk have been effectively restricted to the study of conjugated equine oestrogens (CEE, Premarin). Table I shows the results of seven studies which have considered the effect of the daily dose of CEE. All except one (Kelsey et al., 1982) found that the risk was greater for doses of 1.25 mg day-1 (and above) than for doses of 0.625mg day-1 (and below), although in two studies this trend was not adjusted for duration of use. Table II shows the effect of the two doses, 0.625 mg and 1.25 mg, of CEE on plasma E2, SHBG and estimated E2 binding. Although the lower dose of CEE produces a plasma E2 concentration approximately at the level of the 50pgml-1 upper limit, the accompanying increase in SHBG results in non-protein bound and non-SHBG bound E2 concentrations less than those of the upper limit.
The existence of a dose-effect relationship between endometrial cancer risk and CEE doses of 0.625mgday-1 and 1.25mgday-1 is therefore consistent with the postulated upper limit for effective oestrogen. (Note: plasma E2 Not adjusted for (1979) . Obesity leads to increased peripheral production of El from androstenedione (Siiteri & MacDonald, 1973) , and plasma concentrations of both El and E2 are positively correlated with body weight in postmenopausal women (Judd et al., 1976) . Obesity is also strongly associated with a decrease in SHBG concentration (Anderson, 1974) and thus with an increase in the proportions of non-protein bound and of non-SHBG bound E2. This increase in total E2, and more specifically in bioavailable E2, is commonly considered to be the cause of the increased endometrial cancer risk of obese postmenopausal women (Siiteri, 1978) . Table III shows the relative risks associated with varying degrees of obesity found in four studies. Risk increases steadily with increasing weight. There is no suggestion that there is an upper limit of obesity beyond which risk does not increase further: for this result to be directly compatible with the postulated upper limit to effective oestrogen concentration, even severe obesity should not be associated with a plasma E2 concentration (or bioavailable E2 concentration) which exceeds the 50 pg ml-1 limit. (Table V) . The reduction in risk appears to be directly related to the number of cigarettes smoked, and Baron (1984) proposed that this was due to an anti-oestrogenic effect of smoking. Two studies, including that with the largest number of premenopausal women (Tyler et al., 1985) found that the protective effect of smoking was confined to postmenopausal women, but two smaller recent studies found a protective effect in both premenopausal and postmenopausal women.
A few studies have investigated oestrogen metabolism in smokers. MacMahon et al. (1982) reported that premenopausal luteal phase urinary excretion rates of El, E2 and oestriol (E3) were each reduced in smokers by -30%. They found no changes in the follicular phase, and therefore suggested that the observed lower luteal phase oestrogen excretion of smokers was due to reduced ovarian production rather than changes in liver metabolism. Michnovicz et al. (1986) , however, found that smokers had lower follicular phase urinary excretion of El and E3 than non-smokers (by 47% and 66% respectively): they explained these changes bApproximate body weight of a woman of neight 1.626m and ideal body weight; cEstimated from mean E2 and SHBG concentrations, using the regression equations given by Moore et al. (1983) .
by the increased 2-hydroxylation of E2 (to inactive metabolites), which they found in smokers in both the follicular and the luteal phase. Jensen et al. (1985) found that smoking reduced the serum concentrations of El and E2 in postmenopausal women taking ERT: they could not detect any effect of smoking on endogenous El or E2 concentrations, but these concentrations were at the lower limit of sensitivity of their assay. They concluded that smoking increases metabolic clearance of E2. A recent small study found no differences in serum El and E2 concentrations between postmenopausal smokers and non-smokers (Friedman et al., 1987) , but the smokers in this study had reached menopause more recently than the non-smokers. Further studies of the effects of smoking on endogenous oestrogens are required, but it is of interest to examine the predicted effects of any anti-oestrogenic actions of smoking in premenopausal and postmenopausal women.
In postmenopausal women, any smoking induced decrease in E2 will cause a reduction in endometrial mitotic rate and therefore in the risk of endometrial cancer, because the E2 levels are in the range of 5-20 pg ml-1, well below the 50pgml-1 upper limit. In premenopausal women, small or moderate decreases in E2 will have a smaller effect because even if the early follicular phase E2 drops below the 50 pg ml upper limit, the progressive rise in E2 concentration during the follicular phase will bring the concentration above the limit by day 9 or 10, so that endometrial mitotic activity will only be reduced for a few days of each cycle. This is consistent with the tentative conclusion one may draw from the results shown in Table V (Zumoff, 1982) , but is certainly associated with a decrease in SHBG and therefore with an increase in bioavailable E2. As we discussed above, an increase in bioavailable E2 is commonly considered to be the cause of the increased endometrial cancer risk of obese postmenopausal women. It is clear, however, that increased bioavailable E2 levels cannot be the cause of the increased risk in obese premenopausal women, since the plasma concentration of E2 in premenopausal women is always at or above the upper limit for effective oestrogen action. This suggests that the mechanism by which obesity increases risk in premenopausal women involves progesterone deficiency rather than E2 excess. This is consistent with evidence that obesity is associated with amenorrhoea (Rogers & Mitchell, 1952) , with subnormal luteal phase progesterone concentration (Sherman & Korenman, 1974) , and with irregular menstrual periods (Hartz et al., 1984; Willett et al., 1985) . The endometrium of a woman with 'normal' ovulatory cycles proliferates for 14 days in the cycle, i.e. for only some 50% of the time, but the endometrium of a woman with progesterone deficiency proliferates for more, possibly considerably more, than 50% of the time. Since it is the periods of proliferation that increase endometrial cancer risk, these women will be at an increased risk of endometrial cancer, as is observed.
Hormone replacement therapy The addition of a progestagen to ERT, a regime commonly termed hormone replacement therapy (HRT), has been recommended as a method to prevent the increase in risk of endometrial cancer which is associated with ERT; 12 to 14 days of progestagen during each 28 days of oestrogen is considered to be the optimum regime, because clinical study has shown that this treatment schedule reduces the incidence of endometrial hyperplasia to very low levels (Studd et al., 1980; Whitehead et al., 1982) . The unopposed oestrogen hypothesis maintains, however, that the crucial variable which determines the risk of endometrial cancer is the average mitotic rate (equivalent to the total number of cell divisions) over the 28 day treatment cycle. Mitotic activity during 14 days of treatment with oestrogen alone will be close to the premenopausal follicular phase rate, while during 14 days of oestrogen and progestagen mitotic activity will be negligible, mimicking the luteal phase of the menstrual cycle. This activity has to be compared to the constant but generally very low mitotic rate in untreated postmenopausal women. The average endometrial mitotic rate in women on HRT will thus be considerably greater than the rate in untreated women (with the possible exception of extremely obese women, who are rarely given HRT). We are therefore reasonably certain that HRT will lead to an increased risk of endometrial cancer. The increased risk from HRT will not be as great as that observed with ERT, and no reliable data are yet available on the magnitude of the risk. [We feel that methodological shortcomings in the studies of Gambrell (1986) menopause.) The age-incidence curve for breast cancer, which has a similar shape, has been mathematically analysed in terms of the multistage theory of carcinogenesis (Moolgavkar et al., 1980) and Figure 2 could also be analysed in these terms. Such an analysis leads naturally to consideration of which stage of carcinogenesis is affected by various factors and in certain circumstances this is desirable. The breast cancer age incidence curve has, however, also been mathematically analysed directly in terms of differing mitotic rates at differing ages, without the complexity of defining the stages of carcinogenesis (Pike et al., 1983) . We have adopted this latter approach here since the purpose of this paper is to examine the effects of various factors on cancer incidence through their effects on endometrial cell mitotic rates, rather than to attempt to identify which stage or stages of carcinogenesis are affected.
Mathematical analysis of Figure 2 shows that it is completely compatible with the mitotic rate ideas expressed above (Pike, 1987) , and the effects of the various hormonal factors can be seen most easily by considering their effects on the age-incidence curve (Figure 3) . Although the curves shown in Figure 3 are calculated from the mathematical formulae given in Pike (1987) , they are best considered as having been drawn by modifying the average curve ( Figure  2 ) in the obvious ways.
The long-established protective effect of early menopause is illustrated in Figure 3a , in which menopause at age 50 ('normal') is compared with menopause at age 40. The obvious change here is that the curve for early menopause has the reduced slope of the postmenopausal period starting at age 40. The most important point to notice from the figure is that protection is lifelong.
The mitotic activity of the endometrium in a woman on HRT roughly mimics the premenopausal period. This is illustrated in Figure 3b for 5 years of HRT use starting at menopause (taken as at age 50). Instead of the slope of the incidence curve decreasing at menopause, it simply continues to increase at the premenopausal rate for the 5 years of HRT before changing slope to that normal for the postmenopausal period. The increased risk from HRT use will be lifelong. The figure shows that 5 years of such HRT will increase risk by some 90%, but this is probably an overestimate because the mitotic rate during the unopposed oestrogen phase of lower dose HRT (0.625mg day-1 of CEE) is probably somewhat lower than the rate in the premenopausal follicular phase. If the peak mitotic rate on HRT is taken as two-thirds the follicular level (to agree with the non-SHBG bound E2 level in Table II ) then the estimated 90% increase is reduced to a 50% increase.
The endometrial mitotic activity in a woman on continuous ERT is nearly equal to that during the follicular phase of the menstrual cycle, and the total mitotic activity over a 28-day period is thus roughly double that of a premenopausal woman. This is illustrated in Figure 3b for 5 years of ERT use starting at menopause (taken as at age 50). Instead of the slope of the incidence curve decreasing at age 50, or not changing as shown for HRT, the slope will actually be steeper for the 5 years of ERT. The increased risk will be lifelong, and the figure predicts that 5 years of such ERT use will increase risk by some 280%. With the two-thirds premenopausal rate assumption discussed above the estimated increase in risk is reduced from 280% to 145%. If the two-thirds assumption is made and ERT is only given for 21 days with a seven-day break in each treatment cycle, the estimated increase in risk is further reduced to a 90% increase.
Since endometrial mitotic activity is near zero in women on COCs, the incidence curve will be very nearly flat during the time COCs are used. When COCs are stopped the curve will increase as before, just as if the time on COCs did not exist. This is illustrated in Figure 3c for 5 years COC use starting at age 28. The protection against endometrial cancer is lifelong. The figure shows that five years of COC use will decrease risk by some 60%.
Finally Figure 3d illustrates the effect of obesity on the age-incidence curve. In this figure we show the predicted curve for a woman whose obesity makes her anovular from age 35. Her endometrial mitotic rate for ages 35 to 50 is twice the normal premenopausal rate. After menopause her mitotic rate is equal to the normal premenopausal rate [half the follicular rate because bioavailable E2 is approximately half the basal follicular level (see Tables II and IV) , but for double the time (no luteal phase)]. We note that although the curves continue to separate further after menopause (i.e. the relative risk continues to increase), a large proportion of the increased risk in the postmenopausal period is due to the increased mitotic rate in the premenopausal period.
The magnitudes of the risks illustrated in Figure 3 and discussed above are close to those observed in epidemiological studies. The long-term effects of menopause are well known, and long-term benefits of COC use have been observed in a number of studies [see Centers for Disease Control (1983) ]. The recent large study of ERT use (Shapiro et al., 1985) also found that the increase in risk persisted for many years; the apparently contrary findings of some earlier studies were very probably due to misdiagnoses of endometrial hyperplasia as cancer (Horwitz and Feinstein, 1986) . No adequate studies of HRT have yet been reported. 
